Boston, MA, September 23, 2026 – Rezera Inc. (the “Company”), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3
Rezera has aligned with regulators on trial design of Phase 3 study of ruvonoflast in peripheral artery disease (PAD), expected to initiate in 1H of
Rezera plans to advance ruvonoflast into a Phase 3 clinical trial in peripheral artery disease (PAD) in H1 of 2027 Boston, MA, September 9, 2026
Boston, MA, September 2, 2026 – NodThera, a leading clinical-stage company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers
With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen
Round includes participation from Medtronic and top healthcare investors MIAMI, July 16, 2026 (GLOBE NEWSWIRE) — RapidPulse, Inc., a medical technology company developing next-generation aspiration
Data published in the Journal of the American College of Cardiology Represents first peer-reviewed publication of clinical data demonstrating reductions in cardiometabolic risk markers with
Boston, MA, May 19, 2026 – NodThera, the leading clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory
ATLANTA, May 14, 2026 /PRNewswire/ — Nyra Medical, a leading innovator in structural heart therapies, today announced its participation in the upcoming EuroPCR meeting, where the company
Brighton, UK, 12 May 2026: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives